Deep vein thrombosis: cost-effective management of a major health problem

Free article

Editorial

M M Goetghebeur. Value Health. 2000 Nov-Dec.

Free article

. 2000 Nov-Dec;3(6):387-8.

doi: 10.1046/j.1524-4733.2000.36064.x.

No abstract available

Comment on

Economic evaluation of enoxaparin vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients.
Pechevis M, Detournay B, Pribil C, Fagnani F, Chalanson G. Pechevis M, et al. Value Health. 2000 Nov-Dec;3(6):389-96. doi: 10.1046/j.1524-4733.2000.36008.x. Value Health. 2000. PMID: 16464198
Economic evaluation of enoxaparin as postdischarge prophylaxis for deep vein thrombosis (DVT) in elective hip surgery.
Davies LM, Richardson GA, Cohen AT. Davies LM, et al. Value Health. 2000 Nov-Dec;3(6):397-406. doi: 10.1046/j.1524-4733.2000.36005.x. Value Health. 2000. PMID: 16464199